Flag of the European Union EU Clinical Trials Register Help

Clinical trials for CD23

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    49 result(s) found for: CD23. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2013-000506-37 Sponsor Protocol Number: ECWM-1 Start Date*: 2014-10-31
    Sponsor Name:University Hospital Ulm
    Full Title: Efficacy of first line Dexamethasone, Rituximab and Cyclophosphamide (DRC) +/- Bortezomib for patients with Waldenström's Macroglobulinemia
    Medical condition: Waldenström's Macroglobulinemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) IT (Ongoing) PT (Prematurely Ended) SE (Completed) GR (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2005-001502-11 Sponsor Protocol Number: ML18434 Start Date*: 2005-07-18
    Sponsor Name:Roche Austria GmbH
    Full Title: “CHAIROS” – Early brief intensification by chemoimmunotherapy with FCR followed by FR and Rituximab maintenance in chemonaive patients with B-CLL – A phase II study
    Medical condition: Chronic lymphocytic leukemia (CLL)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-001965-41 Sponsor Protocol Number: BRD/06/052 Start Date*: 2008-09-05
    Sponsor Name:University College London
    Full Title: Phase III, multicentre, randomised study of fludarabine/cyclophosphamide combination with or without Rituximab in patients with untreated mantle cell lymphoma
    Medical condition: Mantle Cell Lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-004824-19 Sponsor Protocol Number: ML21206 Start Date*: 2008-08-08
    Sponsor Name:Roche Austria GmbH
    Full Title: Bevacizumab in Chronic Lymphocytic Leukemia: a proof of concept study
    Medical condition: Chronic Lymphocytic Leukemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-022681-27 Sponsor Protocol Number: O-DEX-1 Start Date*: 2010-11-09
    Sponsor Name:University Hospital Brno
    Full Title: Ofatumumab Added to Dexamethasone in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia
    Medical condition: Patients with refractory/relapsed CLL
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-004741-17 Sponsor Protocol Number: SPC2996-101 Start Date*: 2005-05-09
    Sponsor Name:Santaris Pharma
    Full Title: SPC2996 in Chronic Lymphocytic Leukaemia An open-labelled, international multicenter dose escalating, phase I/II study of SPC2996, an LNA antisense molecule against Bcl-2, in patients with relapsed...
    Medical condition: Chronic Lymphocytic Leukaemia (CLL) is the most common leukaemia in adults in the US and most of Western Europe. The incidence is 8100 to 12500 new cases in the US per year. CLL is a relatively ind...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-000844-31 Sponsor Protocol Number: VBP15-BMD-001 Start Date*: 2023-05-18
    Sponsor Name:ReveraGen BioPharma Inc.
    Full Title: A Phase II Pilot Trial of Vamorolone vs. Placebo for the Treatment of Becker Muscular Dystrophy
    Medical condition: Becker Muscular Dystrophy
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003761-16 Sponsor Protocol Number: 9818P Start Date*: 2005-11-24
    Sponsor Name:Department of R & D, Central Manchester and Manchester Children's Hospital NHS Trust
    Full Title: Evaluation of pneumococcal conjugate vaccine (Prevenar) in patients with myeloma and chronic lymphocytic leukaemia
    Medical condition: Pneumococcal disease is a common form of meningitis, septicaemia and pneumonia. Those individuals at highest risk include children, the elderly and persons whose immune systems are impaired. This l...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-003631-36 Sponsor Protocol Number: RG_12-124 Start Date*: 2015-02-10
    Sponsor Name:University of Birmingham
    Full Title: CALiBRe: Assessment of the Mechanism of Action of idelalisib (CAL-101) in B-cell Receptor Pathway Inhibition in CLL
    Medical condition: Chronic lymphocytic leukaemia
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10068852 B-cell chronic lymphocytic leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2007-003081-18 Sponsor Protocol Number: BRD/07/137 Start Date*: 2008-09-29
    Sponsor Name:University College Hospital
    Full Title: Phase II study of low intensity allogeneic transplantation in Mantle Cell Lymphoma
    Medical condition: Mantle Cell Lymphoma (MCL) is an increasingly recognised yet rare sub-type of non-hodgkin's Lymphoma (NHL), representing between 5 and 8% of all cases. Typically a disease of the elderly with a me...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-024389-23 Sponsor Protocol Number: 114813 Start Date*: 2011-06-07
    Sponsor Name:Department of Hematology
    Full Title: A Phase 2 Trial of Alemtuzumab-Ofatumumab Combination in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia
    Medical condition: Chronic Lymphocytic Leukemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004362-95 Sponsor Protocol Number: ECWM-2 Start Date*: 2019-04-12
    Sponsor Name:University Hospital Ulm
    Full Title: Efficacy of first line Bortezomib, Rituximab, Ibrutinib (B-RI) for patients with treatment naive Waldenström’s Macroglobulinemia
    Medical condition: Waldenström's Macroglobulinemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10047801 Waldenstrom's macroglobulinaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-002110-12 Sponsor Protocol Number: GO28667 Start Date*: 2014-02-26
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A MULTICENTER, PHASE III, OPEN-LABEL, RANDOMIZED STUDY IN RELAPSED/REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TO EVALUATE THE BENEFIT OF GDC-0199 (ABT-199) PLUS RITUXIMAB COMPARED WITH...
    Medical condition: Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10068852 B-cell chronic lymphocytic leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SE (Completed) BE (Completed) GB (GB - no longer in EU/EEA) AT (Completed) IT (Completed) FR (Completed) NL (Completed) HU (Completed) DK (Completed) DE (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-004454-17 Sponsor Protocol Number: ACE-CL-309 Start Date*: 2016-10-24
    Sponsor Name:Acerta Pharma BV
    Full Title: A Randomized, Multicenter, Open-Label, Phase 3 Study of Acalabrutinib (ACP-196) Versus Investigator’s Choice of Either Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Subjects with Rela...
    Medical condition: Relapsed or Refractory Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10008978 Chronic lymphocytic leukemia refractory LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Trial now transitioned) SK (Completed) SE (Completed) ES (Ongoing) CZ (Trial now transitioned) AT (Completed) DE (Completed) FR (Completed) BG (Completed) PL (Trial now transitioned) HR (Trial now transitioned) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002443-28 Sponsor Protocol Number: ACE-CL-311/D8221C00001 Start Date*: 2019-05-08
    Sponsor Name:Acerta Pharma B.V.
    Full Title: A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination with Venetoclax with and without Obinutuzumab Compared to Investiga...
    Medical condition: Previously untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10009310 CLL LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Restarted) HU (Trial now transitioned) CZ (Trial now transitioned) SK (Trial now transitioned) PL (Trial now transitioned) GB (GB - no longer in EU/EEA) FR (Trial now transitioned) DK (Trial now transitioned) SE (Trial now transitioned) BG (Trial now transitioned) NL (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-002987-24 Sponsor Protocol Number: 152CL201 Start Date*: 2007-06-25
    Sponsor Name:Biogen Idec Ltd
    Full Title: A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Safety and Efficacy of Lumiliximab in Combination with Fludarabine, Cyclophosphamide, and Rituximab Versus Fludarabine, Cyclopho...
    Medical condition: Relapsed Chronic Lymphocytic Leukemia (CLL)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10008956 Chronic lymphatic leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) AT (Prematurely Ended) ES (Completed) IT (Prematurely Ended) FR (Completed) DE (Prematurely Ended) GB (Completed) CZ (Prematurely Ended) SK (Completed) PT (Prematurely Ended) LT (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-005811-16 Sponsor Protocol Number: OMB110913 Start Date*: 2008-12-22
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A Phase III, Open Label, Randomized Trial of Ofatumumab Added to Fludarabine-Cyclophosphamide vs. Fludarabine-Cyclophosphamide Combination in Subjects with Relapsed Chronic Lymphocytic Leukemia
    Medical condition: Chronic Lymphocytic Leukaemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) GR (Completed) IT (Completed) ES (Completed) GB (Completed) BG (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2008-004932-19 Sponsor Protocol Number: OMB110911 Start Date*: 2009-01-27
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A phase III, open label, randomized, multicenter trial of Ofatumumab added to Chlorambucil vs. Chlorambucil Monotherapy in previously untreated patients with Chronic Lymphocytic Leukemia
    Medical condition: Chronic Lymphocytic Leukaemia
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008976 Chronic lymphocytic leukemia LLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    17.0 10005329 - Blood and lymphatic system disorders 10024324 Leukaemias HLGT
    17.0 10005329 - Blood and lymphatic system disorders 10005329 Blood and lymphatic system disorders SOC
    17.0 10005329 - Blood and lymphatic system disorders 10024295 Leukaemias chronic lymphocytic HLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008959 Chronic lymphocytic leukaemia (in remission) PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) IE (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) SE (Completed) BE (Prematurely Ended) CZ (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended) GR (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-022332-37 Sponsor Protocol Number: PCO Start Date*: 2010-11-16
    Sponsor Name:AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA` GRANDA (A.O. DI RILIEVO NAZIONALE)
    Full Title: A SINGLE-ARM MULTI-CENTER TRIAL OF PENTOSTATIN PLUS CYCLOPHOSPHAMIDE WITH OFATUMUMAB (PCO) IN OLDER PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA
    Medical condition: patients with previously untreated CLL
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005329 SOC
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-015909-39 Sponsor Protocol Number: INT5909 Start Date*: 2009-12-02
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: Phase I/II trial of dexamethasone, ofatumumab and bendamustine [Treanda] (DOT) as first-line treatment of mantle-cell lymphoma (MCL) in the elderly
    Medical condition: Mantle-cell lymphoma (MCL)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061275 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 29 16:30:43 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA